Another study shows that the in utero administration of a well-recognized Nrf2 inducer, sulforaphane, can inhibit hyperoxia-induced lung inflammation in neonatal mice, but the inhibition of alveolar growth is not improved in this model of BPD [53]. This evidence concerns the gene NFE2L2 and bronchopulmonary dysplasia.